QQQ   425.76 (-0.02%)
AAPL   167.88 (-0.07%)
MSFT   408.36 (-0.84%)
META   506.07 (+2.41%)
GOOGL   155.94 (+0.30%)
AMZN   181.21 (-0.04%)
TSLA   150.48 (-3.20%)
NVDA   845.83 (+0.65%)
AMD   154.69 (+0.44%)
NIO   3.99 (+2.05%)
BABA   69.24 (+0.61%)
T   16.16 (+0.25%)
F   12.09 (+0.42%)
MU   116.92 (+0.51%)
GE   157.72 (+1.32%)
CGC   7.06 (+8.78%)
DIS   113.39 (+0.40%)
AMC   2.79 (-6.38%)
PFE   25.35 (-0.28%)
PYPL   63.07 (-0.30%)
XOM   119.05 (+0.35%)
QQQ   425.76 (-0.02%)
AAPL   167.88 (-0.07%)
MSFT   408.36 (-0.84%)
META   506.07 (+2.41%)
GOOGL   155.94 (+0.30%)
AMZN   181.21 (-0.04%)
TSLA   150.48 (-3.20%)
NVDA   845.83 (+0.65%)
AMD   154.69 (+0.44%)
NIO   3.99 (+2.05%)
BABA   69.24 (+0.61%)
T   16.16 (+0.25%)
F   12.09 (+0.42%)
MU   116.92 (+0.51%)
GE   157.72 (+1.32%)
CGC   7.06 (+8.78%)
DIS   113.39 (+0.40%)
AMC   2.79 (-6.38%)
PFE   25.35 (-0.28%)
PYPL   63.07 (-0.30%)
XOM   119.05 (+0.35%)
QQQ   425.76 (-0.02%)
AAPL   167.88 (-0.07%)
MSFT   408.36 (-0.84%)
META   506.07 (+2.41%)
GOOGL   155.94 (+0.30%)
AMZN   181.21 (-0.04%)
TSLA   150.48 (-3.20%)
NVDA   845.83 (+0.65%)
AMD   154.69 (+0.44%)
NIO   3.99 (+2.05%)
BABA   69.24 (+0.61%)
T   16.16 (+0.25%)
F   12.09 (+0.42%)
MU   116.92 (+0.51%)
GE   157.72 (+1.32%)
CGC   7.06 (+8.78%)
DIS   113.39 (+0.40%)
AMC   2.79 (-6.38%)
PFE   25.35 (-0.28%)
PYPL   63.07 (-0.30%)
XOM   119.05 (+0.35%)
QQQ   425.76 (-0.02%)
AAPL   167.88 (-0.07%)
MSFT   408.36 (-0.84%)
META   506.07 (+2.41%)
GOOGL   155.94 (+0.30%)
AMZN   181.21 (-0.04%)
TSLA   150.48 (-3.20%)
NVDA   845.83 (+0.65%)
AMD   154.69 (+0.44%)
NIO   3.99 (+2.05%)
BABA   69.24 (+0.61%)
T   16.16 (+0.25%)
F   12.09 (+0.42%)
MU   116.92 (+0.51%)
GE   157.72 (+1.32%)
CGC   7.06 (+8.78%)
DIS   113.39 (+0.40%)
AMC   2.79 (-6.38%)
PFE   25.35 (-0.28%)
PYPL   63.07 (-0.30%)
XOM   119.05 (+0.35%)
NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

$14.69
+0.01 (+0.07%)
(As of 10:20 AM ET)
Today's Range
$14.67
$14.71
50-Day Range
$13.62
$15.00
52-Week Range
$11.53
$15.89
Volume
14,524 shs
Average Volume
110,923 shs
Market Capitalization
$213.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MACK stock logo

About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

MACK Stock Price History

MACK Stock News Headlines

AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
Merrimack Reports Full Year 2023 Financial Results
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
MACK Mar 2024 14.000 put
MACK Mar 2024 4.000 put
MACK Feb 2024 16.000 put
Ipsen drug approved by FDA for early pancreatic cancer
Merrimack Pharmaceuticals Inc MACK
Merrimack Reports Third Quarter 2023 Financial Results
See More Headlines
Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/18/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MACK
CUSIP
59032810
Employees
426
Year Founded
2000

Profitability

Net Income
$-1,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.31 per share

Miscellaneous

Free Float
10,337,000
Market Cap
$213.45 million
Optionable
Optionable
Beta
1.43

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

MACK Stock Analysis - Frequently Asked Questions

How have MACK shares performed in 2024?

Merrimack Pharmaceuticals' stock was trading at $13.41 at the beginning of the year. Since then, MACK stock has increased by 9.5% and is now trading at $14.68.
View the best growth stocks for 2024 here
.

When is Merrimack Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MACK earnings forecast
.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter.

When did Merrimack Pharmaceuticals' stock split?

Merrimack Pharmaceuticals's stock reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MACK) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners